Drug intelligence / Profile preview

SKB500

Development stage: Phase 2
Lead developer: Kelun-Biotech
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SKB500 is a novel antibody-drug conjugate (ADC) developed by Sichuan Kelun-Biotech Biopharmaceutical. It targets B7-H3, a protein overexpressed in various solid tumors, and is designed to deliver cytotoxic agents directly to tumor cells expressing this antigen. The drug is currently being evaluated in Phase 1 clinical trials for safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity in patients with advanced solid tumors. SKB500 was developed using Kelun's proprietary OptiDC platform.

Targets

B7-H3

Beyond the preview

Go deeper on SKB500.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKB500.

Explore the full profile